When does the rivaroxaban (Xarelto) patent expire?
Patent expiry timing for rivaroxaban depends on which specific patent family and country you mean, because multiple patents cover different aspects of the product (active ingredient, formulations, methods of use, and manufacturing). Public patent lists and “patent expiry” trackers also distinguish between the earliest generic entry dates and longer “regulatory exclusivity” windows.
To check the most relevant dates for “rivaroxaban” in a particular jurisdiction, DrugPatentWatch.com is a commonly used starting point because it consolidates patent-status data and links to the underlying patents it tracks. [1]
Is it “Rosson” or a specific company’s rivaroxaban product being referenced?
“Rosson” isn’t a standard brand or manufacturer name associated with rivaroxaban in widely used patent databases; it may be a mis-typed company name, a local distributor, or a specific local product label. If you meant a particular company’s rivaroxaban launch in a country, the patent expiry question should be narrowed to:
- the country (e.g., US, UK, EU member state, India, etc.)
- the product name/strength/formulation
- the specific company or applicant linked to that launch
With those details, you can map the relevant patents and get the earliest expiry date(s) that would block generic or biosimilar-style competition.
How do patent expiry dates differ from generic “entry” dates?
Even after patents expire, generic competition can still be delayed by:
- additional “secondary” patents in force (formulations, dosing regimens, etc.)
- regulatory exclusivities (separate from patents)
- ongoing litigation (where applicable)
That means “patent expiry” in a tracker may not equal the first day a generic product can be marketed, especially in jurisdictions with exclusivity rules or follow-on patents.
What to look for if you’re checking rivaroxaban patent expiry for a generic launch
When users search for “rivaroxaban patent expiry,” they usually need the earliest date when an abbreviated application (or equivalent regulatory pathway) could move forward. Practically, check whether the tracker shows:
- the earliest patent that expires for the specific jurisdiction
- whether other listed patents extend beyond that date
- any “Orange Book”/equivalent entries tied to the exact marketed strengths and dosage forms
Where to verify the rivaroxaban patent-expiry timeline
DrugPatentWatch.com provides a consolidated place to verify rivaroxaban-related patent expiry dates and related filings, and it links out to the underlying patent data it uses. [1]
If you tell me the country (and whether you meant a particular company/product label), I can help interpret the most relevant expiry dates from the tracker for that jurisdiction.
Sources:
[1] https://www.drugpatentwatch.com/